» Articles » PMID: 36512269

Intracellular Labile Iron is a Key Regulator of Hepcidin Expression and Iron Metabolism

Overview
Journal Hepatol Int
Publisher Springer
Specialty Gastroenterology
Date 2022 Dec 13
PMID 36512269
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Liver iron loading can induce hepatic expression of hepcidin and regulate iron metabolism. However, the mechanism by which hepatocyte senses iron loading and further regulates iron metabolism remains unclear. Intracellular labile iron is nonferritin-bound and redox active; it is transitory, and it serves as a crossroads of cellular iron metabolism, the effect of intracellular labile iron in iron metabolism regulation is particularly poorly understood.

Methods: An intracellular labile iron overload cell model was established using ferric ammonium citrate (FAC) and the lipophilic iron chelator 8-hydroxyquinoline (8HQ/FAC). RNA-Seq was performed to screen the genes that were highly expressed exclusively in 8HQ/FAC-treated HepG2 cells. High-iron-diet mice model and Hfe knockout hemochromatosis mice were used to investigate the importance of tumor necrosis factor α (TNFα) in iron metabolism.

Results: Intracellular labile iron in hepatocytes had a dual function in iron metabolism: It induced hepatocytes to express hepcidin via endoplasmic reticulum stress-induced transcription factors, and it stimulated expression of bone morphogenic protein 6 (BMP6, regulator of iron metabolism) in liver sinusoidal endothelial cells (LSECs) via promoting the secretion of TNFα by the hepatocytes. Blockade of TNFα dysregulated iron metabolism during iron overload. Furthermore, administration of TNFα could reduce iron burden in Hfe knockout hemochromatosis mice.

Conclusions: Our findings reveal the importance of intracellular labile iron in iron metabolism, and propose that TNFα might be a novel therapeutic target for HFE-associated hemochromatosis.

Citing Articles

Sodium Butyrate Inhibits Necroptosis by Regulating MLKL via E2F1 in Intestinal Epithelial Cells of Liver Cirrhosis.

Zhou Y, Ding Y, Li Y, Sheng Q, Han C, Fan Y J Clin Transl Hepatol. 2025; 13(2):105-117.

PMID: 39917471 PMC: 11797820. DOI: 10.14218/JCTH.2024.00221.


Ferroptosis as an emerging target in sickle cell disease.

Fortuna V, Lima J, Oliveira G, Oliveira Y, Getachew B, Nekhai S Curr Res Toxicol. 2024; 7:100181.

PMID: 39021403 PMC: 11252799. DOI: 10.1016/j.crtox.2024.100181.


TIMP-1 Promotes Expression of MCP-1 and Macrophage Migration by Inducing Fli-1 in Experimental Liver Fibrosis.

Huang X, Wang X, Wang Y, Shen S, Chen W, Liu T J Clin Transl Hepatol. 2024; 12(7):634-645.

PMID: 38993513 PMC: 11233975. DOI: 10.14218/JCTH.2023.00514.


Serum Iron Overload Activates the SMAD Pathway and Hepcidin Expression of Hepatocytes via SMURF1.

Zhang N, Yang P, Li Y, OuYang Q, Hou F, Zhu G J Clin Transl Hepatol. 2024; 12(3):227-235.

PMID: 38426189 PMC: 10899870. DOI: 10.14218/JCTH.2023.00440.


Spotlight on iron and ferroptosis: research progress in diabetic retinopathy.

Ouyang J, Zhou L, Wang Q Front Endocrinol (Lausanne). 2023; 14:1234824.

PMID: 37772084 PMC: 10525335. DOI: 10.3389/fendo.2023.1234824.


References
1.
Bonkovsky H . Iron and the liver. Am J Med Sci. 1991; 301(1):32-43. DOI: 10.1097/00000441-199101000-00006. View

2.
Corradini E, Meynard D, Wu Q, Chen S, Ventura P, Pietrangelo A . Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology. 2011; 54(1):273-84. PMC: 3277401. DOI: 10.1002/hep.24359. View

3.
Ramos E, Kautz L, Rodriguez R, Hansen M, Gabayan V, Ginzburg Y . Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology. 2011; 53(4):1333-41. PMC: 3074982. DOI: 10.1002/hep.24178. View

4.
Arosio P, Ingrassia R, Cavadini P . Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta. 2008; 1790(7):589-99. DOI: 10.1016/j.bbagen.2008.09.004. View

5.
Rothman R, Serroni A, Farber J . Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury. Mol Pharmacol. 1992; 42(4):703-10. View